Results 281 to 290 of about 1,468,461 (396)

New antibody approaches to lymphoma therapy [PDF]

, 2014

core   +1 more source

Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Decision‐making in haemophilia is challenging due to the small evidence base, disease heterogeneity, and inter‐patient variability. Shared decision‐making (SDM) supports patient‐clinician decisions. Aim Creation of a two‐sided decision box facilitating SDM for haemophilia patients switching from conventional (weight‐based) to ...
Arun Keepanasseril, Athena Mancini, Megan S. Lowe, Noella Noronha, Alfonso Iorio   +4 more
wiley   +1 more source

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Haemophilia, EarlyView.
ABSTRACT Background Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives To estimate FVIIIeq of emicizumab using global assays of haemostasis.
Daniel Kraemmer, Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge   +6 more
wiley   +1 more source

Platforms for studying cell–cell recognition by immune cells

Immunology &Cell Biology, EarlyView.
This review compares different platforms for studying how immune cells integrate signals from co‐signaling receptor‐ligand interactions at cell–cell interfaces. By understanding the strengths and weaknesses of each platform, including which factors can be controlled by the user, immunologists can identify the most appropriate platform to address their ...
Jordan Kramer, P Anton van der Merwe, Omer Dushek   +2 more
wiley   +1 more source

Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia

Internal Medicine Journal, EarlyView.
Abstract The survival of newly diagnosed patients with multiple myeloma has improved significantly over the past 20 years with significant therapeutic advances. Despite this, high‐dose chemotherapy followed by autologous stem cell transplantation remains the standard of care in newly diagnosed patients who are considered transplant eligible.
Georgia McCaughan, Hayley Beer, Christian Bryant, P. Joy Ho, Tracy King, Cindy Lee, Peter Mollee, H. Miles Prince, Andrew Spencer, Dipti Talaulikar, Kate Vandyke, Nicholas Weber, Angelina Yong, Simon Harrison, Hang Quach   +14 more
wiley   +1 more source

Impact of cellular composition and T‐cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T‐cells

Transfusion, EarlyView.
Abstract Background Apheresis procedure of autologous lymphocytes competent for proliferation and expansion is a crucial step in the production of chimeric antigen receptor (CAR) T‐cells. Previous therapies or disease status prior to collection may negatively impact the collections.
Vladan Vučinić, Theresa Tumewu, Mandy Brückner, Janine Kirchberg, Madlen Jentzsch, Raymund Buhmann, Yvonne Remane, Sandra Hoffmann, Florian Ramdohr, Maximilian Merz, Klaus H. Metzeler, Sebastian Schwind, Carmen Herling, Simon M. Krauß, Marco Herling, Georg‐Nikolaus Franke, Nora Grieb, Georg Stachel, Martin Janz, Olaf Penack, Lars Bullinger, Ulrich Keller, Michael Cross, Reinhard Henschler, Enrica Bach, Uwe Platzbecker   +25 more
wiley   +1 more source

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments.
Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo   +9 more
wiley   +1 more source

Alternative Immunosuppression in Acquired Haemophilia A

Haemophilia, EarlyView.
Jayna Mistry, Gillian Lowe, Will Lester, Charles Percy   +3 more
wiley   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, Volume 157, Issue 5, Page 954-963, 1 September 2025.
What's new? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

MedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi, Izuchukwu F. Okpalanwaka, Adenike Oyegbesan, Ebenezar Okoyeocha, Mariam Oladejo, Sikiru O. Imodoye   +5 more
wiley   +1 more source